Table 3. Multivariate analyses used to... | American Society of Hematology

Table 3.

Multivariate analyses used to determine the prognostic significance of FLT3-ITD MRD status over time

Clinical and genetic variables	CIR		OS
Clinical and genetic variables	HR (95% CI)	P	HR (95% CI)	P
Patients	N = 157
Events	n = 35		n = 59
Age (10 y-increase)	0.99 (0.96-1.02)	.644	1.03 (1.01-1.06)	.016
Female	0.36 (0.17-0.76)	.007	0.57 (0.33-0.97)	.038
WBC (log₁₀)	0.91 (0.48-1.74)	.779	0.67 (0.40-1.12)	.129
BM blasts	1.00 (0.98-1.01)	.769	1.00 (0.99-1.01)	.882
NPM1^mut	0.34 (0.16-0.71)	.004	0.90 (0.49-1.65)	.727
FLT3-ITD^high	1.16 (0.51-2.64)	.715	1.28 (0.69-2.36)	.437
HCT in CR1	0.17 (0.08-0.38)	<.001	0.95 (0.50-1.82)	.885
FLT3-ITD MRD^pos∗	6.83 (2.72-17.13)	<.001	3.32 (1.69-6.54)	<.001
Patients	n = 110
Events	n = 21		n = 36
Age (10 y-increase)	0.99 (0.95-1.03)	.597	1.03 (0.99-1.07)	.106
Female	0.34 (0.13-0.89)	.028	0.48 (0.24-0.95)	.034
WBC (log₁₀)	0.82 (0.36-1.87)	.646	0.56 (0.29-1.09)	.087
BM blasts	0.99 (0.97-1.02)	.603	1.00 (0.99-1.02)	.630
NPM1^mut	0.42 (0.13-1.28)	.126	1.00 (0.39-2.58)	.998
FLT3-ITD^high	1.52 (0.50-4.66)	.464	1.30 (0.57-2.93)	.534
HCT in CR1	0.09 (0.03-0.27)	<.001	1.30 (0.59-2.86)	.508
FLT3-ITD MRD^conv∗	9.94 (2.24-44.22)	.003	2.83 (0.98-8.18)	.055

Clinical and genetic variables	CIR		OS
Clinical and genetic variables	HR (95% CI)	P	HR (95% CI)	P
Patients	N = 157
Events	n = 35		n = 59
Age (10 y-increase)	0.99 (0.96-1.02)	.644	1.03 (1.01-1.06)	.016
Female	0.36 (0.17-0.76)	.007	0.57 (0.33-0.97)	.038
WBC (log₁₀)	0.91 (0.48-1.74)	.779	0.67 (0.40-1.12)	.129
BM blasts	1.00 (0.98-1.01)	.769	1.00 (0.99-1.01)	.882
NPM1^mut	0.34 (0.16-0.71)	.004	0.90 (0.49-1.65)	.727
FLT3-ITD^high	1.16 (0.51-2.64)	.715	1.28 (0.69-2.36)	.437
HCT in CR1	0.17 (0.08-0.38)	<.001	0.95 (0.50-1.82)	.885
FLT3-ITD MRD^pos∗	6.83 (2.72-17.13)	<.001	3.32 (1.69-6.54)	<.001
Patients	n = 110
Events	n = 21		n = 36
Age (10 y-increase)	0.99 (0.95-1.03)	.597	1.03 (0.99-1.07)	.106
Female	0.34 (0.13-0.89)	.028	0.48 (0.24-0.95)	.034
WBC (log₁₀)	0.82 (0.36-1.87)	.646	0.56 (0.29-1.09)	.087
BM blasts	0.99 (0.97-1.02)	.603	1.00 (0.99-1.02)	.630
NPM1^mut	0.42 (0.13-1.28)	.126	1.00 (0.39-2.58)	.998
FLT3-ITD^high	1.52 (0.50-4.66)	.464	1.30 (0.57-2.93)	.534
HCT in CR1	0.09 (0.03-0.27)	<.001	1.30 (0.59-2.86)	.508
FLT3-ITD MRD^conv∗	9.94 (2.24-44.22)	.003	2.83 (0.98-8.18)	.055

FLT3-ITD^high, FLT3-internal tandem duplication with AR ≥0.5; MRD^conv, conversion from MRD negative after Cy2 of intensive chemotherapy to MRD positive over time; MRD^pos, MRD positive at any time point.

∗

As time-dependent variable.

View Large

This Feature Is Available To Subscribers Only